Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EBITDA (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed EBITDA for 10 consecutive years, with -$32.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 21.94% to -$32.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.9 million through Dec 2025, up 20.57% year-over-year, with the annual reading at -$49.9 million for FY2025, 20.57% up from the prior year.
  • EBITDA for Q4 2025 was -$32.0 million at Rein Therapeutics, down from -$5.6 million in the prior quarter.
  • The five-year high for EBITDA was -$1.8 million in Q2 2023, with the low at -$41.0 million in Q4 2024.
  • Average EBITDA over 5 years is -$9.1 million, with a median of -$6.8 million recorded in 2021.
  • The sharpest move saw EBITDA surged 77.81% in 2023, then tumbled 453.54% in 2024.
  • Over 5 years, EBITDA stood at -$6.8 million in 2021, then skyrocketed by 33.99% to -$4.5 million in 2022, then crashed by 64.6% to -$7.4 million in 2023, then crashed by 453.54% to -$41.0 million in 2024, then rose by 21.94% to -$32.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$32.0 million, -$5.6 million, and -$6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.